Spots Global Cancer Trial Database for A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Official Title: LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor
Study ID: NCT04042116
Study Description
Brief Summary: This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
UC San Diego Moores Cancer Center, San Diego, California, United States
Anschutz Cancer Pavilion, Aurora, Colorado, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke University School of Medicine, Durham, North Carolina, United States
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Tennessee Oncology, Nashville, Tennessee, United States
Swedish Cancer Institute, Seattle, Washington, United States
Medical University of Innsbruck, Innsbruck, , Austria
Saint Luc Univerisity Hospital, Brussels, , Belgium
University Hospital Ghent, Ghent, , Belgium
University Hospitals Leuven, Campus Gasthuisberg, Leuven, , Belgium
University Hospital Carl Gustav Carus, Dresden, , Germany
Kliniken Essen-Mitte, Essen, , Germany
University Hospital Mannhein, Mannheim, , Germany
Polyclinic S. Orsola-Malpighi, Bologna, , Italy
National Cancer Institute -IRCCS "Fondazione G. Pascale, Naples, , Italy
Foundation IRCCS Hospital Agostino Gemelli, Rome, , Italy
University Hospital Reina Sofia, Cordoba, Andalusia, Spain
University Hospital Vall d'Hebron, Barcelona, , Spain
Navarra University Clinic, Madrid, , Spain
La Paz University Hospital, Madrid, , Spain
Contact Details
Name: Erika Hamilton, MD
Affiliation: Tennessee Oncology, PLLC
Role: PRINCIPAL_INVESTIGATOR
Name: Nicole Concin, MD
Affiliation: KEM Kliniken Essen Mitte Evang. Huyssens-Stiftung
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
